<DOC>
	<DOC>NCT02784236</DOC>
	<brief_summary>Prospective study of 6 months of evolution in people with type 1 diabetes with insulin multidose (MDI) and HbA1c&gt; 7%. Patients were evaluated clinical, metabolic and psychological baseline and at 6 months, with a telematic visit at 3 months. We analyzed: glycemic control (HbA1c), glycemic variability (SD and MAGE), depressive symptoms (BDI-II), anxiety (STAI), treatment-related (DDS) distress, fear of hypoglycemia (FH-15), adhesion treatment (SCI-R), quality of life (DQOL) and treatment satisfaction (DTSQ) and the platform.</brief_summary>
	<brief_title>INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Patients with DM1 plus 1 year of evolution. Age ≥18 and &lt;65 years. HbA1c prior to study inclusion&gt; 7%. MDI intensive insulin therapy in basalbolus regimen. Patients candidates for telemonitoring. Approximately 50% of the patients should work with phone or tablet with Android operating system with active data rate to use wireless solution (bluetooth) OnLine MenaDiab® telemedicine. The remaining patients will work with the USB cable solution telemedicine MenaDiab® OnLine. Patients who have given written informed consent. Treatment with ISCI. Chronic kidney disease, liver disease, thyroid dysfunction (hypothyroidism except properly treated and controlled). Pregnant or planning pregnancy. Diabetes mellitus type 2. Severe psychological disorders. Lack of cooperation (informed consent). Patients who are participating in other clinical studies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>